Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Cerilliant
US Department of Justice
Cantor Fitzgerald
Mallinckrodt
Citi
Deloitte
Fish and Richardson

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202258

« Back to Dashboard

NDA 202258 describes VICTRELIS, which is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are three patents protecting this drug. Additional details are available on the VICTRELIS profile page.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
Summary for 202258
Tradename:VICTRELIS
Applicant:Merck Sharp Dohme
Ingredient:boceprevir
Patents:3
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:CAPSULE;ORALStrength200MG
Approval Date:May 13, 2011TE:RLD:No
Patent:➤ Sign UpPatent Expiration:Nov 11, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
Patent:➤ Sign UpPatent Expiration:Mar 17, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
Patent:➤ Sign UpPatent Expiration:Dec 22, 2024Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
US Army
Accenture
Chinese Patent Office
McKinsey
Cerilliant
Mallinckrodt
QuintilesIMS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.